scholarly journals Diffuse optical tomography of the breast: a potential modifiable biomarker of breast cancer risk with neoadjuvant chemotherapy

2019 ◽  
Vol 10 (8) ◽  
pp. 4305
Author(s):  
Mirella L. Altoe ◽  
Alessandro Marone ◽  
Hyun K. Kim ◽  
Kevin Kalinsky ◽  
Dawn L. Hershman ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Breast Cancer Risk ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Risk ◽  
Optical Tomography ◽  
Diffuse Optical Tomography

scholarly journals Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomography

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Mirella L. Altoe ◽  
Kevin Kalinsky ◽  
Alessandro Marone ◽  
Hyun K. Kim ◽  
Hua Guo ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Optical Tomography ◽  
Pathologic Complete Response ◽  
Negative Relationship ◽  
Diffuse Optical Tomography ◽  
Complete Response ◽  
Normal Breast ◽  
Mixed Effect ◽  
Tumor Bearing

Abstract Background The purpose of this study is to evaluate whether the changes in optically derived parameters acquired with a diffuse optical tomography breast imager system (DOTBIS) in the contralateral non-tumor-bearing breast in patients administered neoadjuvant chemotherapy (NAC) for breast cancer are associated with pathologic complete response (pCR). Methods In this retrospective evaluation of 105 patients with stage II–III breast cancer, oxy-hemoglobin (ctO2Hb) from the contralateral non-tumor-bearing breast was collected and analyzed at different time points during NAC. The earliest monitoring imaging time point was after 2–3 weeks receiving taxane. Longitudinal data were analyzed using linear mixed-effects modeling to evaluate the contralateral breast ctO2Hb changes across chemotherapy when corrected for pCR status, age, and BMI. Results Patients who achieved pCR to NAC had an overall decrease of 3.88 μM for ctO2Hb (95% CI, 1.39 to 6.37 μM), p = .004, after 2–3 weeks. On the other hand, non-pCR subjects had a non-significant mean reduction of 0.14 μM (95% CI, − 1.30 to 1.58 μM), p > .05. Mixed-effect model results indicated a statistically significant negative relationship of ctO2Hb levels with BMI and age. Conclusions This study demonstrates that the contralateral normal breast tissue assessed by DOTBIS is modifiable after NAC, with changes associated with pCR after only 2–3 weeks of chemotherapy.

Diffuse optical tomography of breast cancer during neoadjuvant chemotherapy: A case study with comparison to MRI

2005 ◽  
Vol 32 (4) ◽  
pp. 1128-1139 ◽  
Author(s):  
Regine Choe ◽  
Alper Corlu ◽  
Kijoon Lee ◽  
Turgut Durduran ◽  
Soren D. Konecky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Neoadjuvant Chemotherapy ◽  
Optical Tomography ◽  
Diffuse Optical Tomography

scholarly journals Background Parenchymal Enhancement on Breast MRI: Assessment and Clinical Implications

2021 ◽  
Vol 9 (10) ◽  
Author(s):  
James S. Chalfant ◽  
Shabnam Mortazavi ◽  
Stephanie A. Lee-Felker
Keyword(s):  
Breast Cancer ◽  
Clinical Practice ◽  
Breast Cancer Risk ◽  
Neoadjuvant Chemotherapy ◽  
Cancer Risk ◽  
Quantitative Assessment ◽  
Breast Mri ◽  
Clinical Implications ◽  
Background Parenchymal Enhancement ◽  
Parenchymal Enhancement

Abstract Purpose of Review To present recent literature regarding the assessment and clinical implications of background parenchymal enhancement on breast MRI. Recent Findings The qualitative assessment of BPE remains variable within the literature, as well as in clinical practice. Several different quantitative approaches have been investigated in recent years, most commonly region of interest-based and segmentation-based assessments. However, quantitative assessment has not become standard in clinical practice to date. Numerous studies have demonstrated a clear association between higher BPE and future breast cancer risk. While higher BPE does not appear to significantly impact cancer detection, it may result in a higher abnormal interpretation rate. BPE is also likely a marker of pathologic complete response after neoadjuvant chemotherapy, with decreases in BPE during and after neoadjuvant chemotherapy correlated with pCR. In contrast, pre-treatment BPE does not appear to be predictive of pCR. The association between BPE and prognosis is less clear, with heterogeneous results in the literature. Summary Assessment of BPE continues to evolve, with heterogeneity in approaches to both qualitative and quantitative assessment. The level of BPE has important clinical implications, with associations with future breast cancer risk and treatment response. BPE may also be an imaging marker of prognosis, but future research is needed on this topic.

Sign in / Sign up

Export Citation Format

Share Document